[Effects of low dose mifepristone on population and subsets of natural killer cells in human endometrium during receptive phase].
To investigate the immunologic mechanism of low dose mifepristone as an anti-implantation contraceptive drug. Endometrial biopsies were obtained from fourteen normally cycling women during the receptive phase. Each endometrial tissue, divided into three equal parts, was assigned to three groups: control group, 65 nmol/L mifepristone group (group A) and 200 nmol/L mifepristone group (group B). Endometrial explants were cultured in vitro. The numbers of natural killer cells and the percentages of CD3- CD56+ CD16- subset and CD3- CD56+ CD16+ subset were analysed by immunohistochemistry and flow cytometry. (1) The mean number of CD56+ NK cells in group A (148 +/- 11) and group B (150 +/- 12) were significantly higher when compared to the control group (121 +/- 7, P < 0.05). There was no significant difference between the two mifepristone-treated groups (P > 0.05). (2) The percentage of CD3- CD56+ Nk cells in group A (44 +/- 5)% and in group B (48 +/- 4)% were significantly higher when compared to the control group (35 +/- 3)% (P < 0.05), there was no significantly difference between the two mifepristone-treated groups (P > 0.05); The percentage of CD3- CD56+ CD16- subset in group A (42 +/- 5)% and in group B (45 +/- 5)% were significantly higher when compared to the control group (33 +/- 3)%, (P < 0.05), there was no significantly difference between the two mifepristone-treated groups (P > 0.05); the percentages of CD3- CD56+ CD16+ subset in three groups [(2.70 +/- 0.24)% (3.26 +/- 0.37)% and (2.33 +/- 0.29)%] were not significantly different (P > 0.05). Low dose mifepristones increase the number of CD56+ NK cells and the percentage of CD3- CD56+ CD16- NK subset, which might result in the disturbance of human endometrial immuno-microenvironment during receptive phase and lead to implantation failure.